Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. Additionally, it is used in inflammatory conditions including rheumatoid arthritis. Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this research has now been discontinued. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Somalgen and Talniflumatum. Its PubChem CID is 48229.
Talniflumate
| CAS No | 66898-62-2 |
|---|---|
| Molecular Formula | C21H13F3N2O4 |
| Molecular Weight | 414.3 g/mol |
| Synonyms | (3-oxo-1H-2-benzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma.
The listed CAS number is 66898-62-2.
The listed molecular formula is C21H13F3N2O4.
The listed molecular weight is 414.3 g/mol.
(3-oxo-1H-2-benzofuran-1-yl) 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate.
The source lists Somalgen and Talniflumatum.